Area of research
Cancer Research · Oncology
Research interest
Research interests include Breast Cancer Treatment Studies, HER2/EGFR in Cancer Research, Cancer, Lipids, and Metabolism, and Epigenetics and DNA Methylation.
Sentinel lymph node biopsy using dye alone in patients with initial clinical N1 breast cancer receiving neoadjuvant therapy: A multicenter diagnostic trial (Northern Breast Cancer Collaboration Group NBCG-002).
The small nucleolar RNA SNORA51 enhances breast cancer stem cell-like properties via the RPL3/NPM1/c-MYC pathway.
[18F]FDG PET-CT radiomics signature to predict pathological complete response to neoadjuvant chemoimmunotherapy in non-small cell lung cancer: a multicenter study
Efficacy analysis of neoadjuvant chemotherapy with or without anthracyclines in female patients with HER2-positive breast cancer in China: a nationwide, multicenter, 10-year retrospective study (CSBrS-012)
POR overexpression induces tamoxifen-resistance in breast cancer through the STAT1/c-Myc pathway.
Safety of COVID-19 Vaccination in Patients With Breast Cancer: Cross-Sectional Study in China
Safety and Current Status of the COVID-19 Vaccine among Patients with Breast cancer: A Cross-Sectional Study from China
Safety of COVID-19 Vaccination in Patients With Breast Cancer: Cross-Sectional Study in China.
Exploration of Specific Population for Adjuvant Capecitabine Escalation Therapy in Early-Stage Triple-Negative Breast Cancer: A Retrospective Biological Sample Analysis of the CBCSG010 Clinical Trial
Safety of COVID-19 Vaccination in Patients With Breast Cancer: Cross-Sectional Study in China (Preprint)
Prognostic and predictive value of the newly proposed grading system of invasive pulmonary adenocarcinoma in Chinese patients: a retrospective multicohort study
A novel HIF-2α targeted inhibitor suppresses hypoxia-induced breast cancer stemness via SOD2-mtROS-PDI/GPR78-UPR<sup>ER</sup> axis.
CACA Guidelines for Holistic Integrative Management of Breast Cancer
Expert consensus on the clinical diagnosis and targeted therapy of HER2 breast cancer (2023 edition)
A Novel Prognostic Signature of Immune-Related Long Noncoding RNA Pairs for Tumor-Infiltrating Immune Cells and Drug Susceptibility in Breast Cancer.
<i>XRCC5/6</i> polymorphisms and their interactions with smoking, alcohol consumption, and sleep satisfaction in breast cancer risk: A Chinese multi‐center study
DEAD-box helicase 27 enhances stem cell-like properties with poor prognosis in breast cancer.
Genome-wide 5-Hydroxymethylcytosine Profiling Analysis Identifies MAP7D1 as A Novel Regulator of Lymph Node Metastasis in Breast Cancer.
Clinical information and management status of de novo stage IV breast cancer patients: a Chinese multicenter investigation (CSBrS-002)
Relationship Between Lifestyle Habits and Health-Related Quality of Life of Recently Diagnosed Breast Cancer Patients: A Comparison Between Younger and Older Women in China
Assessment of CPS + EG, Neo-Bioscore and Modified Neo-Bioscore in Breast Cancer Patients Treated With Preoperative Systemic Therapy: A Multicenter Cohort Study
DEAD-Box Helicase 27 Enhances Stem Cell-Like Properties With Poor Prognosis in Breast Cancer
Mapping Neutralizing and Immunodominant Sites on the SARS-CoV-2 Spike Receptor-Binding Domain by Structure-Guided High-Resolution Serology
Adjuvant Capecitabine With Docetaxel and Cyclophosphamide Plus Epirubicin for Triple-Negative Breast Cancer (CBCSG010): An Open-Label, Randomized, Multicenter, Phase III Trial
Treatment of coronavirus disease 2019 in Shandong, China: a cost and affordability analysis
Immune-related lncRNAs as predictors of survival in breast cancer: a prognostic signature.
Current Status and Factors Influencing Surgical Options for Breast Cancer in China: A Nationwide Cross-Sectional Survey of 110 Hospitals
Chinese expert consensus on the clinical diagnosis and treatment of advanced breast cancer (2018)
Prevalence of symptomatic dry eye in breast cancer patients undergoing systemic adjuvant treatment: A cross-sectional study.
Immune-related lncRNAs as predictors of survival in breast cancer: a prognostic signature